RxDoctor Payments Data

Iain Black, PA

Physician Assistant · Peoria, AZNPI 1376798421

Payments from drug & device makers

$6,163in general payments, 2019–2025

Across 373 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$2K
  • Johnson & Johnson$326
  • GSK$325
  • Pfizer$248
  • UCB, Inc.$245
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$6,08599%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,163 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$308,014
Medicare patients
147
Services billed
18,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab84$830,324
Enbrel SureclickEtanercept59$548,324
Humira PenAdalimumab18$231,314
Xeljanz XrTofacitinib Citrate29$171,559
SimponiGolimumab24$169,795
Humira(Cf)Adalimumab24$160,240
RinvoqUpadacitinib22$149,614
ProliaDenosumab54$95,488
XeljanzTofacitinib Citrate14$94,127
ActemraTocilizumab33$51,774
Actemra ActpenTocilizumab13$35,477
LyricaPregabalin27$16,878
Hydroxychloroquine Sulfate538$16,821
Leflunomide139$6,213
MethotrexateMethotrexate Sodium405$5,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Rinvoq$1,685$309,85446 claims
Johnson & JohnsonSimponi$326$169,79524 claims
PfizerXeljanz, Lyrica$248$111,00541 claims
AmgenProlia$1,904$95,48854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →